Scholar Rock Holding (SRRK) Amortization of Deferred Charges (2019 - 2026)

Scholar Rock Holding's (SRRK) quarterly Amortization of Deferred Charges came in at $1.5 million in Q1 2026, up 24.09% year-on-year from $1.2 million in Q1 2025, and up 11.19% quarter-over-quarter from $1.4 million in Q4 2025.

Scholar Rock Holding (SRRK) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends

Scholar Rock Holding's Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.

  • On a quarterly basis, Amortization of Deferred Charges rose 24.09% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 12.95% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, up 0.73% from the prior year.
  • Amortization of Deferred Charges advanced to $1.5 million in Q1 2026 per SRRK's latest filing, from $1.4 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $6.9 million in Q4 2023 and bottomed at -$3.4 million in Q3 2023.
  • The 5-year median for Amortization of Deferred Charges is $1.3 million (2025), against an average of $1.2 million.
  • Across the five-year window, Amortization of Deferred Charges surged 4601.36% in 2023 and sank 96.86% in 2024, its largest moves.
  • Year by year, Amortization of Deferred Charges stood at $147000.0 in 2022, then jumped by 4601.36% to $6.9 million in 2023, then slipped by 27.39% to $5.0 million in 2024, then plunged by 72.4% to $1.4 million in 2025, then grew by 11.19% to $1.5 million in 2026.
  • Per Business Quant, the three latest SRRK Amortization of Deferred Charges figures stand at $1.5 million (Q1 2026), $1.4 million (Q4 2025), and $1.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,094.26 Bn 68,093.97 Bn -
2 Nanobiotix 1,939.09 Bn 1,939.02 Bn -
3 Akari Therapeutics 1,132.35 Bn 1,132.35 Bn -
4 BeOne Medicines 473.53 Bn 468.74 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.34 Bn 116.09 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.13 Bn 61.38 Bn 3.31 Bn
7 Belite Bio 62.96 Bn 62.96 Bn -
8 Argenx Se 56.38 Bn 51.20 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.67 Bn 34.66 Bn 959.66 Mn
10 Scholar Rock Holding 6.28 Bn 6.28 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 1.54 Mn
Mar 31, 2026 1.54 Mn
Dec 31, 2025 1.39 Mn
Dec 31, 2025 1.39 Mn
Sep 30, 2025 1.34 Mn
Sep 30, 2025 1.34 Mn
Jun 30, 2025 1.29 Mn
Jun 30, 2025 1.29 Mn
Mar 31, 2025 1.24 Mn
Mar 31, 2025 1.24 Mn
Dec 31, 2024 5.02 Mn
Dec 31, 2024 5.02 Mn
Sep 30, 2024 71,000.00
Sep 30, 2024 71,000.00
Jun 30, 2024 58,000.00
Jun 30, 2024 58,000.00
Mar 31, 2024 77,000.00
Mar 31, 2024 77,000.00
Dec 31, 2023 6.91 Mn
Dec 31, 2023 6.91 Mn